Results of the intention-to-treat analysis from the COMET study, "a prospective randomized, pragmatic non-inferiority trial..." for women with low-risk ductal carcinoma in situ (DCIS) was recently presented at the San Antonio Breast Cancer Symposium. Conducted on 995 women 40 years or older with a new diagnosis of hormone receptor-positive grade 1 or grade 2 DCIS without invasive cancer, the COMET study supports the notion that a "standard management strategy for low-risk DCIS requires longer follow-up for most patients."
To learn more about the COMET study, click here.
Sources mentioned:
- Hwang ES, Hyslop T, Lynch T, et al. for the COMET Study Investigators. Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ The COMET Randomized Clinical Trial. JAMA; Published online 12 December 2024. doi: 10.1001/jama.2024.26698
- Morrow M, Barrio AV. Is It Time to Abandon Surgery for Low-Risk DCIS? JAMA; Published online 12 December 2024. doi:10.1001/jama.2024.26723
No comments:
Post a Comment